Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Other Operating Expenses for 7 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 47.09% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 58.29% year-over-year, with the annual reading at $13.8 million for FY2025, 58.29% up from the prior year.
  • Other Operating Expenses hit $4.0 million in Q4 2025 for Coherus Oncology, up from $3.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $199.5 million in Q1 2021 to a low of -$108.5 million in Q3 2022.
  • Historically, Other Operating Expenses has averaged $914150.0 across 5 years, with a median of $3.6 million in 2025.
  • Biggest five-year swings in Other Operating Expenses: soared 2810.33% in 2021 and later plummeted 745.25% in 2022.
  • Year by year, Other Operating Expenses stood at $12.1 million in 2021, then tumbled by 745.25% to -$78.1 million in 2022, then decreased by 1.99% to -$79.7 million in 2023, then skyrocketed by 103.45% to $2.8 million in 2024, then soared by 47.09% to $4.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for CHRS at $4.0 million in Q4 2025, $3.7 million in Q3 2025, and $3.4 million in Q2 2025.